Logo-bi
Perspective
Jean J. Latimer* ORCID
Bioimpacts. 2023;13(3): 181-182. doi: 10.34172/bi.2023.27686
PDFPDF
XMLXML
Cited By:
Original Article
Hossein Daghagh ORCID, Haniyeh Rahbar Kafshboran, Yousef Daneshmandpour, Maryam Nasiri Aghdam, Shahrzad Talebian, Jafar Nouri Nojadeh, Hamid Hamzeiy, Saskia Biskup, Ebrahim Sakhinia* ORCID
Bioimpacts. 2023;13(3): 183-190. doi: 10.34172/bi.2022.23528
PDFPDF
XMLXML
Cited By:
Graphical Abstract
Regarding the inheritance pattern in the family and clinical manifestations in the index patient, we propose that the mentioned variant in the CSF1R gene may cause BANDDOS.
Original Article
Roghiyeh Pashaei-Asl ORCID, Maryam Pashaiasl, Esmaeil Ebrahimie, Maryam Lale Ataei, Maliheh Paknejad* ORCID
Bioimpacts. 2023;13(3): 191-206. doi: 10.34172/bi.2022.23813
Graphical Abstract
The application of hAFMSCs-CM, as a therapeutic reagent, can suppress breast cancer cells’ viabilities and induce apoptosis.
Original Article
Forough Alemi ORCID, Masomeh Maleki, Mostafa Mir, Abbas Ebrahimi-Kalan, Mojtaba Zarei, Bahman Yousefi* ORCID, Nadereh Rashtchizadeh* ORCID
Bioimpacts. 2023;13(3): 207-218. doi: 10.34172/bi.2022.23820
PDFPDF
XMLXML
Cited By:
Graphical Abstract
In this work, a graphene oxide-based nanoformulation was designed to deliver a high concentration of doxorubicin to osteosarcoma cancer cells. This nanoformulation showed a better release profile in an acidic condition of tumor site, and higher cytotoxicity and apoptosis rate in comparison to free doxorubicin, which suggests, it is a potential platform for targeted therapy of osteosarcoma.
Original Article
Zhaohui Liu* ORCID, Yanli Meng, Yu Miao, Lili Yu, Qiannan Yu
Bioimpacts. 2023;13(3): 219-228. doi: 10.34172/bi.2023.23585
PDFPDF
XMLXML
Cited By:
Graphical Abstract
Our findings could suggest the use of AS for treating lung disorders through a mechanism involving SIRT1 expression.
Original Article
Diba Ghasemi ORCID, Somayeh Ebrahimi-Barough, Mohammad Hossein Nekoofar, Abdolreza Mohamadnia, Nasrin Lotfibakhshaiesh, Naghmeh Bahrami, Roya Karimi, Vajihe Taghdiri Nooshabadi, Mahmoud Azami, Elham Hasanzadeh, Jafar Ai* ORCID
Bioimpacts. 2023;13(3): 229-240. doi: 10.34172/bi.2022.23960
PDFPDF
XMLXML
Cited By:
Graphical Abstract
The analysis revealed that after a few days of being encapsulated in alginate hydrogel, hEnSCs may grow into oocyte-like cells at a controlled dosage of RA and BMP4, confirming the biocompatibility and safety of the manufactured alginate hydrogel on these differentiated cells.
Original Article
Mina Yousefnezhad, Soodabeh Davaran* ORCID, Mirzaagha Babazadeh, Abolfazl Akbarzadeh, Hamidreza Pazoki-Toroudi
Bioimpacts. 2023;13(3): 241-253. doi: 10.34172/bi.2023.24252
PDFPDF
XMLXML
Cited By:
Graphical Abstract
Drug repurposing is an effective strategy for identifying and using approved drugs for new therapeutic purposes. We investigated co-delivery of the antitumor drugs, doxorubicin (DOX), and ezetimibe (EZ) as a cholesterol uptake-blocking drug with PCEC on prostate cancer cell line (PC3).
Original Article
Mitra Torabi ORCID, Ayuob Aghanejad*, Pouria Savadi ORCID, Abolfazl Barzegari, Yadollah Omidi ORCID, Jaleh Barar* ORCID
Bioimpacts. 2023;13(3): 255-267. doi: 10.34172/bi.2023.25298
PDFPDF
XMLXML
Cited By:
Graphical Abstract
Owing to their unique advantages, mesoporous silica nanoparticles (MSNPs) have attracted much attention for drug delivery and targeting. In the current study, MSNPs were fabricated, PEGylated, loaded with sunitinib, and conjugated with mucin-16 aptamer to target CA125 on ovarian cancer cells.

As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences and provides free editing services. 
Acceptance rate: 24%
First decision: 2-3 days  
Final decision:
3-6 weeks 
Publication fee: Free of charge